EUVIMEDEUVIMED entdecken
Crossref

Clinical Pharmacology of Vancomycin in Pediatrics

Gudisa Bereda

Pharmacy and Drug Development · 2022

DOI: 10.58489/2836-2322/009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy and Drug Development, 2022. Verfasst von Gudisa Bereda. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vancomycin plays an indispensable therapeutic function in managing severe infections caused by MRSA in the children population. Preponderance children dosing references for vancomycin recommend a daily dose of 40 mg/kg/day for empirical treatment, while a dose of 60 mg/kg/day is recommended for CNS infections. Vancomycin is absorbed in fewer amounts through PO in GIT, it is thus IV administered. IV infusions of vancomycin perhaps cause pain, phlebitis, erythema, urticaria, flushing, hypotension, tachycardia and the red man syndrome. Coincident administration of vancomycin with amphotericin-B, NSAIDs, aminoglycosides, cisplatin and other nephrotoxic agents perhaps exaggerated the risk of nephrotoxicity. Concomitant administration of vancomycin and furosemide, aminoglycosides, ethacrynic acid, etc perhaps increase the risk of ototoxicity. Coadministration of vancomycin and vecuronium increases the risk of neuromuscular blockage. If vancomycin and zidovudine are administered together, they increase the risk of neutropenia.

Zitieren

APA

Bereda, G. (2022). Clinical Pharmacology of Vancomycin in Pediatrics. Pharmacy and Drug Development. https://doi.org/10.58489/2836-2322/009

Vancouver

Bereda G. Clinical Pharmacology of Vancomycin in Pediatrics. Pharmacy and Drug Development. 2022. doi:10.58489/2836-2322/009

BibTeX
@article{Bereda2022,
  author = {Bereda, Gudisa},
  title = {Clinical Pharmacology of Vancomycin in Pediatrics},
  journal = {Pharmacy and Drug Development},
  year = {2022},
  doi = {10.58489/2836-2322/009}
}
Kostenlos starten →